

REGION 11 CHICAGO EMS SYSTEM MEDICATION TABLE

Medication Name: Tranexamic acid
Approved: EMS Medical Directors Consortium

Effective: July 10, 2024

| GENERIC NAME | Tranexamic acid |
|--------------------|--|
| TRADE NAME | Cyklokapron; Lysteda |
| CLASSIFICATION | Antifibrinolytic Agent; Antihemophilic Agent; Hemostatic Agent; Lysine Analog |
| DOSAGE FORMS | 1000 mg/ 10 mL, Injection, Vial |
| ACTION(S) | Forms a reversible complex that displaces plasminogen from fibrin resulting in inhibition of fibrinolysis which stabilizes already formed blood clots. |
| | Injury within 3 hours with any of the following: |
| | Trauma (blunt or penetrating) with signs of hemorrhagic shock per Trauma Field Triage Criteria |
| | Penetrating torso trauma |
| | Significant blood loss |
| INDICATIONS | Amputation proximal to the ankle or wrist |
| | Hypersensitivity to tranexamic acid |
| CONTRAINDICATIONS | • Injury ≥ 3 hours |
| ADULT DOSE / ROUTE | 2g IV/IO slow push |
| | • Age < 12 years: 15 mg/kg IV/IO slow push. Max dose 1 gram |
| PEDIATRIC DOSE / | Age 12-15 years: 1 g IV/IO slow push |
| ROUTE | Age ≥ 16 years: 2 g IV/IO slow push |
| SIDE EFFECTS | Seizure, headache, abdominal pain |